Skip to content

Author

N. Alkhouri

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Histologic Features and Clinical Outcomes of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease.

Lean MASLD represents a distinct phenotype with milder histologic disease but similar clinical outcomes compared with overweight/obese MASLD, and the FIB-4 demonstrated lower accuracy for predicting advanced fibrosis in lean vs overweight/obese MASLD.

L. de Avila, K. Al-Naamani, M. Papatheodoridi et al. · 1 citation
Review Sep 2026

International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.

The recent conditional US Food and Drug Administration (FDA) approval of two therapies, resmetirom (Rezdiffra) and semaglutide (Wegovy), marks the first time clinicians have pharmacological therapy for metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis (F2-F3) without cirrhosis, a disease...

Maria Mironova, Vlad Ratziu, M. Rinella et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.